Engineering approaches to immunotherapy

Science Translational Medicine

Volumn 4, Issue 148, 2012, Pages

  Swartz, Melody A ^a   Hirosue, Sachiko ^a   Hubbell, Jeffrey A ^a  

^a EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CHEMOKINE RECEPTOR CCR7; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; LIPOSOME; MACROGOL; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; NANOMATERIAL; POLYACRYLIC ACID; PROPYLENE OXIDE; SECONDARY LYMPHOID TISSUE CHEMOKINE; SUBUNIT VACCINE; TOLL LIKE RECEPTOR; VACCINE; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; BIOENGINEERING; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL HOMING; CELL SURVIVAL; CPG ISLAND; CYTOPLASM; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG RESPONSE; ENDOCYTOSIS; HEPATITIS B; HUMAN; HYDROPHOBICITY; IMMUNOENGINEERING; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; INNATE IMMUNITY; LYMPHOID TISSUE; MICROENVIRONMENT; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; TISSUE ENGINEERING; TRANSLATIONAL RESEARCH;

ANIMALS; BIOENGINEERING; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; NANOSTRUCTURES; TISSUE SCAFFOLDS; VACCINES;

EID: 84865317394     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003763     Document Type: Review

References (94)

1. G. L. Kenausis, J. Voros, D. L. Elbert, N. P. Huang, R. Hofer, L. Ruiz-Taylor, M. Textor, J. A. Hubbell, N. D. Spencer, Poly(L-lysine)-g- poly(ethylene glycol) layers on metal oxide surfaces: Attachment mechanism and effects of polymer architecture on resistance to protein adsorption. J. Phys. Chem. B 104, 3298-3309 (2000).
2. D. L. Elbert, J. A. Hubbell, Self-assembly and steric stabilization at heterogeneous, biological surfaces using adsorbing block copolymers. Chem. Biol. 5, 177-183 (1998).
3. M. P. Lutolf, J. A. Hubbell, Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 23, 47-55 (2005).
4. S. T. Reddy, G. Georgiou, Systems analysis of adaptive immunity by utilization of high-throughput technologies. Curr. Opin. Biotechnol. 22, 584-589 (2011).
5. S. T. Jung, T. H. Kang, W. Kelton, G. Georgiou, Bypassing glycosylation: Engineering aglycosylated full-length IgG antibodies for human therapy. Curr. Opin. Biotechnol. 22, 858-867 (2011).
6. A. M. Cuesta, N. Sainz-Pastor, J. Bonet, B. Oliva, L. Alvarez-Vallina, Multivalent antibodies: When design surpasses evolution. Trends Biotechnol. 28, 355-362 (2010).
7. J. R. Desjarlais, G. A. Lazar, Modulation of antibody effector function. Exp. Cell Res. 317, 1278-1285 (2011).
8. S. Bertholet, G. C. Ireton, D. J. Ordway, H. P. Windish, S. O. Pine, M. Kahn, T. Phan, I. M. Orme, T. S. Vedvick, S. L. Baldwin, R. N. Coler, S. G. Reed, A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci. Transl. Med. 2, 53ra74 (2010).
9. J. A. Hubbell, S. N. Thomas, M. A. Swartz, Materials engineering for immunomodulation. Nature 462, 449-460 (2009).
10. S. T. Reddy, A. J. van der Vlies, E. Simeoni, V. Angeli, G. J. Randolph, C. P. O'Neill, L. K. Lee, M. A. Swartz, J. A. Hubbell, Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25, 1159-1164 (2007).
11. V. Manolova, A. Flace, M. Bauer, K. Schwarz, P. Saudan, M. F. Bachmann, Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404-1413 (2008).
12. M. Sixt, N. Kanazawa, M. Selg, T. Samson, G. Roos, D. P. Reinhardt, R. Pabst, M. B. Lutz, L. Sorokin, The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22, 19-29 (2005).
13. J. J. Moon, H. Suh, C. F. Ockenhouse, A. Yadava, D. J. Irvine, Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl. Acad. Sci. U.S.A. 109, 1080-1085 (2012).
14. A. Stano, A. J. van der Vlies, M. M. Martino, M. A. Swartz, J. A. Hubbell, E. Simeoni, PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Vaccine 29, 804-812 (2011).
15. C. Nembrini, A. Stano, K. Y. Dane, M. Ballester, A. J. van der Vlies, B. J. Marsland, M. A. Swartz, J. A. Hubbell, Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc. Natl. Acad. Sci. U.S.A. 108, E989-E997 (2011).
16. M. Ballester, C.Nembrini, N. Dhar,A. de Titta,C. de Piano,M. Pasquier, E. Simeoni, A. J. van der Vlies, J. D. McKinney, J. A. Hubbell, M. A. Swartz, Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 29, 6959-6966 (2011).
17. B. Pulendran, R. Ahmed, Immunological mechanisms of vaccination. Nat. Immunol. 12, 509-517 (2011).
18. J. J. Moon, H. Suh, A. Bershteyn, M. T. Stephan, H. Liu, B. Huang, M. Sohail, S. Luo, S. H. Um, H. Khant, J. T. Goodwin, J. Ramos, W. Chiu, D. J. Irvine, Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat. Mater. 10, 243-251 (2011).
19. S. Hirosue, I. C. Kourtis, A. J. van der Vlies, J. A. Hubbell, M. A. Swartz, Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine 28, 7897-7906 (2010).
20. S. Foster, C. L. Duvall, E. F. Crownover, A. S. Hoffman, P. S. Stayton, Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy. Bioconjug. Chem. 21, 2205-2212 (2010).
21. S. Cerritelli, D. Velluto, J. A. Hubbell, PEG-SS-PPS: Reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery. Biomacromolecules 8, 1966-1972 (2007).
22. S. P. Kasturi, I. Skountzou, R. A. Albrecht, D. Koutsonanos, T. Hua, H. I. Nakaya, R. Ravindran, S. Stewart, M. Alam, M. Kwissa, F. Villinger, N. Murthy, J. Steel, J. Jacob, R. J. Hogan, A. García-Sastre, R. Compans, B. Pulendran, Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543-547 (2011).
23. C. M. Jewell, S. C. B. López, D. J. Irvine, In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc. Natl. Acad. Sci. U.S.A. 108, 15745-15750 (2011).
24. A. L. St. John, C. Y. Chan, H. F. Staats, K. W. Leong, S. N. Abraham, Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat. Mater. 11, 250-257 (2012).
25. J. S. Rudra, Y. F. Tian, J. P. Jung, J. H. Collier, A self-assembling peptide acting as an immune adjuvant. Proc. Natl. Acad. Sci. U.S.A. 107, 622-627 (2010).
26. J. S. Rudra, T. Sun, K. C. Bird, M. D. Daniels, J. Z. Gasiorowski, A. S. Chong, J. H. Collier, Modulating adaptive immune responses to peptide self-assemblies. ACS Nano 6, 1557-1564 (2012).
27. T. Nochi, Y. Yuki, H. Takahashi, S. Sawada, M. Mejima, T. Kohda, N. Harada, I. G. Kong, A. Sato, N. Kataoka, D. Tokuhara, S. Kurokawa, Y. Takahashi, H. Tsukada, S. Kozaki, K. Akiyoshi, H. Kiyono, Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat. Mater. 9, 572-578 (2010).
28. D. I. Gabrilovich, S. Nagaraj, Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174 (2009).
29. I. Marigo, L. Dolcetti, P. Serafini, P. Zanovello, V. Bronte, Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179 (2008).
30. C. Mesa, J. de León, L. E. Fernández, Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine 24, 2692-2699 (2006).
31. A. Fernández, C. Mesa, I. Marigo, L. Dolcetti, M. Clavell, L. Oliver, L. E. Fernández, V. Bronte, Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J. Immunol. 186, 264-274 (2011).
32. F. Leuschner, P. Dutta, R. Gorbatov, T. I. Novobrantseva, J. S. Donahoe, G. Courties, K. M. Lee, J. I. Kim, J. F. Markmann, B. Marinelli, P. Panizzi, W. W. Lee, Y. Iwamoto, S. Milstein, H. Epstein-Barash, W. Cantley, J. Wong, V. Cortez-Retamozo, A. Newton, K. Love, P. Libby, M. J. Pittet, F. K. Swirski, V. Koteliansky, R. Langer, R. Weissleder, D. G. Anderson, M. Nahrendorf, Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29, 1005-1010 (2011).
33. O. A. Ali, E. Doherty, W. J. Bell, T. Fradet, J. Hudak, M. T. Laliberte, D. J. Mooney, D. F. Emerich, Biomaterial-based vaccine induces regression of established intracranial glioma in rats. Pharm. Res. 28, 1074-1080 (2011).
34. O. A. Ali, D. Emerich, G. Dranoff, D. J. Mooney, In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci. Transl. Med. 1, 8ra19 (2009).
35. J. N. H. Stern, D. B. Keskin, Z. Kato, H. Waldner, S. Schallenberg, A. Anderson, H. von Boehmer, K. Kretschmer, J. L. Strominger, Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 107, 17280-17285 (2010).
36. + T cells into regulatory T cells and promotes immunotolerance in NOD mice. Rev. Diabet. Stud. 7, 47-61 (2010).
37. B. T. Fife, I. Guleria, M. Gubbels Bupp, T. N. Eagar, Q. Tang, H. Bour-Jordan, H. Yagita, M. Azuma, M. H. Sayegh, J. A. Bluestone, Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med. 203, 2737-2747 (2006).
38. X. Luo, K. L. Pothoven, D. McCarthy, M. DeGutes, A. Martin, D. R. Gettss, G. Xia, J. He, X. Zhang, D. B. Kaufman, S. D. Miller, ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc. Natl. Acad. Sci. U.S.A. 105, 14527-14532 (2008).
39. S. Manicassamy, B. Pulendran, Dendritic cell control of tolerogenic responses. Immunol. Rev. 241, 206-227 (2011).
40. D. L. Mueller, Mechanisms maintaining peripheral tolerance. Nat. Immunol. 11, 21-27 (2010).
41. S. E. Tsai, A. Shameli, J. Yamanouchi, X. Clemente-Casares, J. G. Wang, P. Serra, Y. Yang, Z. Medarova, A. Moore, P. Santamaria, Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32, 568-580 (2010).
42. K. Liu, T. Iyoda, M. Saternus, Y. Kimura, K. Inaba, R. M. Steinman, Immune tolerance after delivery of dying cells to dendritic cells in situ. J. Exp. Med. 196, 1091-1097 (2002).
43. L. M. Godsel, K. Wang, B. A. Schodin, J. S. Leon, S. D. Miller, D. M. Engman, Prevention of autoimmune myocarditis through the induction of antigen-specific peripheral immune tolerance. Circulation 103, 1709-1714 (2001).
44. D. J. Irvine, A. N. Stachowiak, Y. Hori, Lymphoid tissue engineering: Invoking lymphoid tissue neogenesis in immunotherapy and models of immunity. Semin. Immunol. 20, 137-146 (2008).
45. M. Cherrier, G. Eberl, The development of LTi cells. Curr. Opin. Immunol. 24, 178-183 (2012).
46. S. A. van de Pavert, R. E. Mebius, New insights into the development of lymphoid tissues. Nat. Rev. Immunol. 10, 664-674 (2010).
47. N. H. Ruddle, E. M. Akirav, Secondary lymphoid organs: Responding to genetic and environmental cues in ontogeny and the immune response. J. Immunol. 183, 2205-2212 (2009).
48. A. Perez, T. C. Grikscheit, R. S. Blumberg, S. W. Ashley, J. P. Vacanti, E. E. Wang, Tissue-engineered small intestine: Ontogeny of the immune system. Transplantation 74, 619-623 (2002).
49. T. C. Grikscheit, F. G. Sala, J. Ogilvie, K. A. Bower, E. R. Ochoa, E. Alsberg, D. Mooney, J. P. Vacanti, Tissue-engineered spleen protects against overwhelming pneumococcal sepsis in a rodent model. J. Surg. Res. 149, 214-218 (2008).
50. S. Suematsu, T. Watanabe, Generation of a synthetic lymphoid tissue-like organoid in mice. Nat. Biotechnol. 22, 1539-1545 (2004).
51. R. Förster, A. C. Davalos-Misslitz, A. Rot, CCR7 and its ligands: Balancing immunity and tolerance. Nat. Rev. Immunol. 8, 362-371 (2008).
52. J. D. Shields, I. C. Kourtis, A. A. Tomei, J. M. Roberts, M. A. Swartz, Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328, 749-752 (2010).
53. A. Manzo, M. Bombardieri, F. Humby, C. Pitzalis, Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: From inflammation to autoimmunity and tissue damage/remodeling. Immunol. Rev. 233, 267-285 (2010).
54. M. A. Swartz, A. W. Lund, Lymphatic and interstitial flow in the tumour microenvironment: Linking mechanobiology with immunity. Nat. Rev. Cancer 12, 210-219 (2012).
55. A. C. Davalos-Misslitz, J. Rieckenberg, S. Willenzon, T. Worbs, E. Kremmer, G. Bernhardt, R. Förster, Generalized multi-organ autoimmunity in CCR7-deficient mice. Eur. J. Immunol. 37, 613-622 (2007).
56. A. L. Fletcher, D. Malhotra, S. J. Turley, Lymph node stroma broaden the peripheral tolerance paradigm. Trends Immunol. 32, 12-18 (2011).
57. A. W. Lund, F. V. Duraes, S. Hirosue, V. R. Raghavan, S. N. Thomas, C. Nembrini, A. Issa, S. Hugues, M. A. Swartz, VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Reports 1, 191-199 (2012).
58. D. H. Munn, A. L. Mellor, The tumor-draining lymph node as an immune-privileged site. Immunol. Rev. 213, 146-158 (2006).
59. I. Kuzin, H. L. Sun, S. Moshkani, C. Y. Feng, A. Mantalaris, J. H. D. Wu, A. Bottaro, Long-term immunologically competent human peripheral lymphoid tissue cultures in a 3D bioreactor. Biotechnol. Bioeng. 108, 1430-1440 (2011).
60. R. A. Clark, K. Yamanaka, M. Bai, R. Dowgiert, T. S. Kupper, Human skin cells support thymus-independent T cell development. J. Clin. Invest. 115, 3239-3249 (2005).
61. G. J. Randolph, S. Beaulieu, S. Lebecque, R. M. Steinman, W. A. Muller, Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 282, 480-483 (1998).
62. H. Song, V. Wittman, A. Byers, T. Tapia, B. Zhou, W. Warren, P. Heaton, K. Connolly, In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine 28, 5524-5532 (2010).
63. A. N. Stachowiak, D. J. Irvine, Inverse opal hydrogel-collagen composite scaffolds as a supportive microenvironment for immune cell migration. J. Biomed. Mater. Res. A 85A, 815-828 (2008).
64. A. A. Tomei, S. Siegert, M. R. Britschgi, S. A. Luther, M. A. Swartz, Fluid flow regulates stromal cell organization and CCL21 expression in a tissue-engineered lymph node microenvironment. J. Immunol. 183, 4273-4283 (2009).
65. M. T. Stephan, D. J. Irvine, Enhancing cell therapies from the outside In: Cell surface engineering using synthetic nanomaterials. Nano Today 6, 309-325 (2011).
66. L. E. Kandalaft, D. J. Powell Jr., N. Singh, G. Coukos, Immunotherapy for ovarian cancer: What's next? J. Clin. Oncol. 29, 925-933 (2011).
67. M. Sadelain, R. Brentjens, I. Riviére, The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21, 215-223 (2009).
68. G. Dotti, B. Savoldo, M. Brenner, Fifteen years of gene therapy based on chimeric antigen receptors: "Are We Nearly There Yet?" Hum. Gene Ther. 20, 1229-1239 (2009).
69. G. Gross, T. Waks, Z. Eshhar, Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. U.S.A. 86, 10024-10028 (1989).
70. Q. Ye, M. Loisiou, B. L. Levine, M. M. Suhoski, J. L. Riley, C. H. June, G. Coukos, D. J. Powell Jr., Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. J. Transl. Med. 9, 131 (2011).
71. M. Kalos, B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, C. H. June, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
72. M. S. Topp, P. Kufer, N. Gökbuget, M. Goebeler, M. Klinger, S. Neumann, H. A. Horst, T. Raff, A. Viardot, M. Schmid, M. Stelljes, M. Schaich, E. Degenhard, R. Köhne-Volland, M. Brüggemann, O. Ottmann, H. Pfeifer, T. Burmeister, D. Nagorsen, M. Schmidt, R. Lutterbuese, C. Reinhardt, P. A. Baeuerle, M. Kneba, H. Einsele, G. Riethmüller, D. Hoelzer, G. Zugmaier, R. C. Bargou, Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493-2498 (2011).
73. M. Klinger, C. Brandl, G. Zugmaier, Y. Hijazi, R. C. Bargou, M. S. Topp, N. Gökbuget, S. Neumann, M. Goebeler, A. Viardot, M. Stelljes, M. Brüggemann, D. Hoelzer, E. Degenhard, D. Nagorsen, P. A. Baeuerle, A. Wolf, P. Kufer, Immunopharmacological response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119, 6226-6233 (2012).
74. P. A. Moore, W. Zhang, G. J. Rainey, S. Burke, H. Li, L. Huang, S. Gorlatov, M. C. Veri, S. Aggarwal, Y. Yang, K. Shah, L. Jin, S. Zhang, L. He, T. Zhang, V. Ciccarone, S. Koenig, E. Bonvini, S. Johnson, Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117, 4542-4551 (2011).
75. M. T. Stephan, J. J. Moon, S. H. Um, A. Bershteyn, D. J. Irvine, Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16, 1035-1041 (2010).
76. G. Zheng, S. Liu, P. Wang, Y. Xu, A. Chen, Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells. Cancer Res. 66, 6793-6799 (2006).
77. M. Notohamiprodjo, R. Djafarzadeh, A. Mojaat, I. von Lüttichau, H. J. Gröne, P. J. Nelson, Generation of GPI-linked CCL5 based chemokine receptor antagonists for the suppression of acute vascular damage during allograft transplantation. Protein Eng. Des. Sel. 19, 27-35 (2006).
78. A. A. Neves, H. Stöckmann, R. R. Harmston, H. J. Pryor, I. S. Alam, H. Ireland-Zecchini, D. Y. Lewis, S. K. Lyons, F. J. Leeper, K. M. Brindle, Imaging sialylated tumor cell glycans in vivo. FASEB J. 25, 2528-2537 (2011).
79. P. V. Chang, J. A. Prescher, E. M. Sletten, J. M. Baskin, I. A. Miller, N. J. Agard, A. Lo, C. R. Bertozzi, Copper-free click chemistry in living animals. Proc. Natl. Acad. Sci. U.S.A. 107, 1821-1826 (2010).
80. L. Buonaguro, B. Pulendran, Immunogenomics and systems biology of vaccines. Immunol. Rev. 239, 197-208 (2011).
81. H. N. Eisen, A. K. Chakraborty, Evolving concepts of specificity in immune reactions. Proc. Natl. Acad. Sci. U.S.A. 107, 22373-22380 (2010).
82. R. N. Germain, M. Meier-Schellerscheim, A. Nita-Lazar, I. D. C. Fraser, Systems biology in immunology: A computational modeling perspective. Annu. Rev. Immunol. 29, 527-585 (2011).
83. B. Pulendran, S. Li, H. I. Nakaya, Systems vaccinology. Immunity 33, 516-529 (2010).
84. B. R. Angermann, F. Klauschen, A. D. Garcia, T. Prustel, F. Zhang, R. N. Germain, M. Meier-Schellersheim, Computational modeling of cellular signaling processes embedded into dynamic spatial contexts. Nat. Methods 9, 283-289 (2012).
85. A. Kosmrlj, E. L. Read, Y. Qi, T. M. Allen, M. Altfeld, S. G. Deeks, F. Pereyra, M. Carrington, B. D. Walker, A. K. Chakraborty, Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465, 350-354 (2010).
86. C. H. Chen, A. Sarkar, Y. A. Song, M. A. Miller, S. J. Kim, L. G. Griffith, D. A. Lauffenburger, J. Han, Enhancing protease activity assay in droplet-based microfluidics using a biomolecule concentrator. J. Am. Chem. Soc. 133, 10368-10371 (2011).
87. N. Varadarajan, B. Julg, Y. J. Yamanaka, H. Chen, A. O. Ogunniyi, E. McAndrew, L. C. Porter, A. Piechocka-Trocha, B. J. Hill, D. C. Douek, F. Pereyra, B. D. Walker, J. C. Love, A high-throughput single-cell analysis of human CD8+ T cell functions reveals discordance for cytokine secretion and cytolysis. J. Clin. Invest. 121, 4322-4331 (2011).
88. L. J. Cruz, P. J. Tacken, F. Bonetto, S. I. Buschow, H. J. Croes, M. Wijers, I. J. de Vries, C. G. Figdor, Multimodal imaging of nanovaccine carriers targeted to human dendritic cells. Mol. Pharm. 8, 520-531 (2011).
89. S. S. Yaghoubi, M. C. Jensen, N. Satyamurthy, S. Budhiraja, D. Paik, J. Czernin, S. S. Gambhir, Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat. Clin. Pract. Oncol. 6, 53-58 (2009).
90. + T cells using microengraving. Proc. Natl. Acad. Sci. U.S.A. 109, 3885-3890 (2012).
91. H. Kalscheuer, N. Danzl, T. Onoe, T. Faust, R.Winchester, R. Goland, E. Greenberg, T. R. Spitzer, D. G. Savage, H. Tahara, G. Choi, Y. G. Yang, M. Sykes, A model for personalized in vivo analysis of human immune responsiveness. Sci. Transl. Med. 4, 125ra30 (2012).
92. S. T. Reddy, X. Ge, A. E. Miklos, R. A. Hughes, S. H. Kang, K. H. Hoi, C. Chrysostomou, S. P. Hunicke-Smith, B. L. Iverson, P. W. Tucker, A. D. Ellington, G. Georgiou, Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat. Biotechnol. 28, 965-969 (2010).
93. M. J. Palmer, V. S. Mahajan, J. Chen, D. J. Irvine, D. A. Lauffenburger, Signaling thresholds govern heterogeneity in IL-7-receptor mediated responses of naïve CD8+ T cells. Immunol. Cell Biol. 89, 581-594 (2011).
94. M. L. Tykocinski, A. Chen, J. H. Huang, M. C. Weber, G. Zheng, New designs for cancer vaccine and artificial veto cells: An emerging palette of protein paints. Immunol. Res. 27, 565-574 (2003).